All News
Filter News
Found 308 articles
-
Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 08, 2022
6/8/2022
Vaxart, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Wednesday, July 6, 2022 at 9:30 a.m. Pacific Time with respect to all proposals described in Vaxart’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2022.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
6/3/2022
Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant.
-
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
6/2/2022
Vaxart (NASDAQ: VXRT) today reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candidate in subjects aged 55 – 80 years (NCT04854746).
-
Vaxart to Participate at the Jefferies Global Healthcare Conference
6/2/2022
Vaxart, Inc. announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 9, 2022 at 10:30 a.m. ET.
-
ChemoCentryx Announces Changes to its Board of Directors
5/31/2022
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
-
Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral
5/26/2022
Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of a promising antiviral treatment, vapendavir.
-
Altesa BioSciences Recognizes Co-Founder and Partner for Major NIH Research Grant to Discover New Antiviral Drugs
5/25/2022
Altesa BioSciences, Inc., today recognized George Painter, PhD, a co-founder of Altesa and chairman of the Altesa Scientific Advisory Board for earning a major research grant from the National Institute of Allergy and Infections Diseases (NIAID), part of the National Institutes of Health.
-
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
5/19/2022
Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that Vaxart’s (NASDAQ: VXRT) S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2.
-
Actym Therapeutics Announces Significant Expansion of Senior Leadership
5/12/2022
Actym Therapeutics announced the significant expansion of its senior leadership team.
-
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
5/9/2022
Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.
-
Vaxart to Present at World Vaccine Congress Washington 2022 on April 20
4/14/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.
-
Downstream Processing Market to reach US$ 25.4 Bn By 2030, Rise in incidence rates of chronic disorders with significant unmet medical needs to drive the market
4/11/2022
According to the report, the global downstream processing market was valued over US$ 6.7 Bn in 2019.
-
Orum Therapeutics Announces Formation of Scientific Advisory Board
4/4/2022
Orum Therapeutics today announced the formation of its scientific advisory board (SAB).
-
NEUVOGEN Appoints Biotechnology Veteran, Mark Backer, PhD as Head of Technical Operations
3/28/2022
NEUVOGEN, an immunoncology company, announced today that Mark Backer , PhD has joined the company as Head of Technical Operations, and will be responsible for leading all aspects of technical operations and chemistry, manufacturing and controls (CMC) technical development for NEUVOGEN's cancer vaccines.
-
Altesa BioSciences Announces Scientific Advisory Board
2/28/2022
Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).
-
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
2/24/2022
A new study published on BioRxiv.org demonstrates that Vaxart’s S-only COVID-19 clinical vaccine candidate, now being studied by Vaxart in Phase II trials, generated antibodies to the original COVID-19 virus strain and to the beta, delta, alpha and gamma variants of SARS-CoV-2 in the serum and nasal mucosa of non-human primates (NHPs).
-
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the fourth quarter and full year 2021, reporting forward momentum for the Company, including its oral norovirus and COVID-19 vaccine candidates.
-
BioSpace Movers & Shakers, Feb. 18
2/18/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
2/14/2022
Vaxart, Inc. announced the appointment of Edward B. Berg as the Company's first in-house General Counsel.